2Stahl S, Zivkov M, Reimitz PE, Panaqides J. Hoff W. Meta-analysis of randomized, double-blind, placebo-controlled. efficacy and safety studies of mirtazapine versus amitriptyline in major depression[J]. Acta psychiatry Scand Suppl, 1997, 391:22. 被引量：1
3Stimmel GL, Dopheide JA. Mirtazapine: an antidepressant with noradrenerqic and specific serotonerqic effects[J]. Pharmacotherapy. 1997, 17:10. 被引量：1
4Fawcett J, Barkin RL. A meta-analysis of eight randomized, double-blind, controlled clinical trials of mirtazapine for the treatment of patients with major depression and symptoms of anxiety[J]. J Clin Psychiatry. 1998.59:123. 被引量：1
5Owens MJ. Knight DL. Nemeroff CB. Second-generation SSRIs: human monoamine transporter binding profile of escitalopram and R-fluoxetine [J]. Biol Psychiatry,2001,50:345. 被引量：1
6Monzgomery SA. Loft H. Sanchez C. Reines EH .Papp M. Escitalopram (S-enantiomer of citalopram ) : clinical efficacy and onset of action predicted from a rat mode[J]. Pharmacol Toxicol, 2001,88:282. 被引量：1
7Burke WJ. Gergel I. Bose A. Fixed-dose trial of the single isomer SSRI escitalopram in depressed outpatients[J].J Clin Psychiatry, 2002,63:331. 被引量：1
8Wade A, Michael Lemming O, Bang Hedegaard K.Esckalopram 10mg/day is effective and well tolerated in a place-controlled study in depression in primary care[J]. Int Clin Psychopharmacol, 2002. 17:95. 被引量：1
9Wond EH. Sonders MS. Amara SG, et al. Reboxetine: a pharmacologically potent, selective, and specific norepinephrine reuptake[J]. Biol Psychiatry. 2000.47: 818. 被引量：1
10Academic highlights. The medicine., current treatment advances in depression[J]. J Clin Psychiatry, 2001, 62(5) : 382. 被引量：1
